This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Been-Tiktak, A. M. Articles by Borleffs, J. C. Search for Related Content PubMed PubMed Citation Articles by Been-Tiktak, A. M. Articles by Borleffs, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 11 1996, 2664-2668, Vol 40, No. 11
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

AM Been-Tiktak, I Williams, HM Vrehen, J Richens, D Aldam, AM van Loon, C Loveday, CA Boucher, P Ward, IV Weller and JC Borleffs
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV- infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.